In a report released on November 7, Brian Skorney from Robert W. Baird maintained a Hold rating on Theravance Biopharma (TBPH – Research Report), with a price target of $8.00. The company’s shares closed yesterday at $10.90.
According to TipRanks, Skorney is an analyst with an average return of -6.8% and a 43.00% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Biogen, Intercept Pharma, and Eiger Biopharmaceuticals.
Currently, the analyst consensus on Theravance Biopharma is a Moderate Buy with an average price target of $13.44, representing a 23.30% upside. In a report released on November 8, Cowen & Co. also maintained a Hold rating on the stock with a $9.33 price target.
See Insiders’ Hot Stocks on TipRanks >>
TBPH market cap is currently $697.9M and has a P/E ratio of -7.59.
Based on the recent corporate insider activity of 40 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TBPH in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Theravance Biopharma, Inc. operates as a biopharmaceutical company. It focuses on the discovery, research, development, and commercialization of organ-selective medicines. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.
Read More on TBPH: